Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Actinogen Medical Ltd is a biotechnology company. The company develops drugs for Alzheimer's disease and the cognitive decline associated with other neurological diseases. Geographically, it operates and derives revenue from Australia. It has developed a product Xanamem.
|17 Sep 2021||$0.10||$0.01||11.11%||4,495,033||$0.09||$0.11||$0.09|
|16 Sep 2021||$0.09||$0.00||0.00%||511,627||$0.09||$0.09||$0.09|
|15 Sep 2021||$0.09||$0.00||0.00%||1,473,064||$0.09||$0.09||$0.09|
|14 Sep 2021||$0.09||$0.00||0.00%||2,373,289||$0.09||$0.10||$0.09|
|13 Sep 2021||$0.09||$0.00||0.00%||1,625,139||$0.09||$0.10||$0.09|
|10 Sep 2021||$0.09||$0.00||0.00%||2,232,713||$0.09||$0.10||$0.09|
|09 Sep 2021||$0.09||$-0.01||-10.00%||6,721,382||$0.10||$0.10||$0.09|
|08 Sep 2021||$0.10||$0.00||0.00%||1,541,449||$0.11||$0.11||$0.10|
|07 Sep 2021||$0.11||$-0.01||-9.09%||8,598,798||$0.11||$0.12||$0.10|
|06 Sep 2021||$0.11||$0.00||0.00%||1,600,896||$0.11||$0.11||$0.11|
|03 Sep 2021||$0.11||$0.01||9.52%||3,800,353||$0.11||$0.11||$0.11|
|02 Sep 2021||$0.11||$0.00||0.00%||1,281,261||$0.11||$0.11||$0.11|
|01 Sep 2021||$0.11||$-0.01||-9.09%||1,686,221||$0.11||$0.11||$0.11|
|31 Aug 2021||$0.11||$0.02||21.28%||4,064,417||$0.10||$0.11||$0.10|
|30 Aug 2021||$0.09||$0.00||0.00%||1,981,694||$0.10||$0.10||$0.09|
|27 Aug 2021||$0.09||$-0.01||-10.00%||3,838,939||$0.10||$0.11||$0.09|
|26 Aug 2021||$0.10||$0.00||0.00%||4,692,410||$0.11||$0.11||$0.10|
|25 Aug 2021||$0.11||$0.01||10.87%||9,252,685||$0.09||$0.11||$0.09|
|24 Aug 2021||$0.09||$0.01||12.82%||9,926,660||$0.08||$0.09||$0.08|
|23 Aug 2021||$0.08||$0.00||0.00%||3,422,486||$0.08||$0.08||$0.08|
|17 Nov 2020||George Morstyn||Issued||40||$880||
|17 Nov 2020||Malcolm McComas||Issued||100||$2,200||
|17 Nov 2020||Geoffrey Brooke||Issued||265||$5,830||
|17 Nov 2020||John (Bill) Ketelbey||Issued||128||$2,828||
Rights issue. As per announcement on 17/11/2020.
|17 Nov 2020||John (Bill) Ketelbey||Issued||1||$40,968||
|Dr George Morstyn||Non-Executive Director||Dec 2017||
Dr Morstyn has more than 25 years; experience in the biotechnology industry including as Senior Vice President of Development and Chief Medical Officer at Amgen Inc. Dr Morstyn had responsibility globally for drug development in all therapeutic areas including neuroscience at Amgen Inc. and was a member of the Operating Committee. Many new products were approved and launched during Dr Morstyn's tenure. Prior to joining Amgen Inc. Dr Morstyn has been a Non-Executive Director of various for-profit and not-for-profit companies, including many biotechnology companies. He is currently on the Board of the Cooperative Research Centre for Cancer Therapeutics, Symbio (Tokyo) and Biomedical Research Victoria.
|Mr Malcolm John McComas||Non-Executive Director||Apr 2019||
Mr McComas has over 25 years of experience in the financial services industry with experience in corporate finance, mergers and acquisitions, debt and equity funding transactions across multiple industry sectors. He held senior leadership roles with Grant Samuel, County NatWest (now Citigroup) and Morgan Grenfell (now Deutsche Bank) in Australia and the UK. Prior to this Mr McComas was a lawyer at Herbert Geer specialising in tax. Mr McComas is an experienced company director and currently services number of listed entities, and also has not-for-profit involvement as a director of the Australasian Leukemia and Lymphoma Group.
|Dr Geoffrey E.D Brooke||Non-Executive ChairmanNon-Executive Director||Feb 2021||
Dr Brooke is a healthcare industry and venture capital veteran with over 30 years' international experience as the founder, lead investor and/or Chairman/Director of numerous healthcare companies. He was the Managing Director and Founder of leading life sciences venture capital firm, GBS Ventures. There, Dr Brooke was responsible for GBS's healthcare venture activity in the region. Dr Brooke was also responsible for numerous investments and exits via NASDAQ and ASX public listings and trade sales, as well as being lead investor in numerous investments syndicated in multiple rounds with premier US venture firms. Dr Brooke was also President and Founder of US-based seed healthcare venture capital firm, Medvest Inc., with investors including the venture capital arm of global multinational medical devices, pharmaceutical and consumer packaged goods manufacturer, Johnson & Johnson. Dr Brooke now acts as a private investor in, and independent director for, a number of small to medium-sized Australian and US private and public companies.
|Dr Steven Gourlay||Chief Executive OfficerManaging Director||Mar 2021||
Dr Gourlay has more than 30 years of experience in the development of novel therapeutics. Formerly the founding Chief Medical Officer (CMO) at US-based Principia Biopharma Inc., Dr Gourlay was responsible for the supervision of multiple pre-clinical, first-in-human, Phase 2 and 3 clinical trial programs for four small molecules in orphan immunological diseases, multiple sclerosis and cancer. The data generated by these trials, and Dr Gourlay's roadshow presentations, supported a NASDAQ IPO of Principia Biopharma Inc. in 2018 - subsequently followed by an acquisition of by Sanofi in 2020. Prior to Principia Biopharma, Dr Gourlay was a Partner at GBS Venture Partners, the Australian specialist life sciences and healthcare venture capital firm, where he was involved in the development and exit of multiple clinical stage therapeutic companies including Elastagen, Spinifex and Peplin. Before GBS, and after a postdoc in clinical pharmacology at the University of California San Francisco, he held positions of increasing responsibility at Genentech, Inc. in the areas of pharmacoepidemiology and early clinical development. Dr Gourlay has drug regulatory experience with the US Food and Drug Administration (FDA), European Medicines Agency (EMA) at many levels, including filing more than 10 Investigational New Drug (IND) applications, achieving several orphan drug status approvals for his Company's product(s), and completing several biologics license applications. Dr Gourlay has been acting as a consultant CMO to Actinogen since December 2020.
|Mr Peter Webse||Company Secretary||
|Peter Webse||Company Secretary||
|HSBC Custody Nominees (Australia) Limited||227,303,623||20.36%|
|Edinburgh Technology Fund Limited||48,147,864||4.31%|
|Surfit Capital Pty Ltd||30,000,000||2.69%|
|Tisia Nominees Pty Ltd (Henderson Family A/C)||27,867,184||2.50%|
|Mrs Sarah Cameron||25,916,573||2.32%|
|Brazil Farming Pty Ltd||15,000,000||1.34%|
|Citicorp Nominees Pty Ltd||10,604,474||0.95%|
|Mr Steven Veronese||10,008,001||0.90%|
|Oaktone Nominees Pty Ltd (Grist Investment A/C)||10,000,000||0.90%|
|Mrs Gillian Karen Nes & Mrs Ronald Nes (Giro S/F A/C)||9,950,000||0.89%|
|Kaleidoscope Holdings Pty Ltd (Kaleidoscope Super A/C)||9,000,000||0.81%|
|Griffin & Grace Investments Pty Ltd (Griffin & Grace Inv S/F A/C)||8,800,000||0.79%|
|Mr Peter James Nixon||8,400,000||0.75%|
|Alua Capital Pty Ltd||8,000,000||0.72%|
|BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd Drp||7,738,901||0.69%|
|BNP Parabis Nominees Pty Ltd (Bnpp Nyb Clearing Acc Drp)||7,560,729||0.68%|
|Bannaby Investments Pty Ltd (Super Fund A/C)||7,500,000||0.67%|
|Webinvest Pty Ltd (Olsb Unit A/C)||7,000,000||0.63%|
|Romfal Sifat Pty Ltd (The Fizmail Family A/C)||7,000,000||0.63%|
|Paranji Super Fund Pty Ltd (Paranji Superfund A/C)||6,500,000||0.58%|